Compounded Semaglutide in El Paso: How Programs Work

Compounded semaglutide is a non-FDA-approved preparation of the GLP-1 receptor agonist semaglutide, made by a state-licensed compounding pharmacy for an individual patient based on a clinician's prescription. In El Paso, men typically access these programs through telehealth, where a US-licensed clinician evaluates eligibility before any treatment is dispensed.

Demand for compounded semaglutide in El Paso has grown alongside interest in GLP-1 therapy for obesity and metabolic disease. West Texas men often turn to telehealth — a clinical evaluation without a long drive, available in English or Spanish, with a treatment plan reviewed by a licensed provider.

What semaglutide is, and what compounding actually means

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a gut hormone the body releases after meals. Activating the GLP-1 receptor slows gastric emptying, modulates appetite signaling in the brain, and improves glucose-dependent insulin secretion (Drucker, Cell Metabolism, 2018). Semaglutide is the active ingredient in three FDA-approved products: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management and cardiovascular risk reduction in adults with obesity and established cardiovascular disease.

Compounded semaglutide is a separate category. State-licensed compounding pharmacies prepare a patient-specific medication under a prescription from a licensed clinician. It is not FDA-approved. It is not interchangeable with Ozempic or Wegovy. The clinical research described below was conducted on the FDA-approved branded products and is attributed to those preparations. A clinician decides whether a compounded preparation is appropriate for a given patient — that decision is not made through a self-checkout cart.

What the published research on semaglutide shows

The strongest body of evidence on semaglutide for weight management comes from the STEP trial program. In STEP 1, adults with overweight or obesity (without diabetes) randomized to weekly semaglutide 2.4 mg experienced a mean body-weight reduction of 14.9% over 68 weeks, compared with 2.4% in the placebo group; both groups received lifestyle intervention (Wilding et al., NEJM, 2021).

Cardiovascular outcomes have been studied separately. In SUSTAIN-6, semaglutide reduced the rate of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk (Marso et al., NEJM, 2016). The SELECT trial extended this finding to a non-diabetic population: among adults with overweight or obesity and established cardiovascular disease, weekly semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% over a mean follow-up of about 39 months (Lincoff et al., NEJM, 2023).

These outcomes apply to the studied FDA-approved products at the studied doses. They are not direct claims about any compounded preparation. A provider weighs the totality of available evidence when discussing options with a patient.

How clinicians evaluate candidates

The American Diabetes Association's Standards of Care in Diabetes — 2024 recommends GLP-1 receptor agonists as a preferred class for adults with type 2 diabetes who would benefit from cardiovascular risk reduction or weight management. For obesity without diabetes, professional guidance from the American Association of Clinical Endocrinology supports pharmacotherapy in adults with a body-mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, sleep apnea, or prediabetes.

A clinician evaluating a patient typically reviews:

• Current medications and a complete medical history, including any prior pancreatitis, thyroid C-cell tumors, gallbladder disease, or family history of medullary thyroid carcinoma or MEN2 syndrome.
• Recent labs — at minimum a metabolic panel and HbA1c, often a lipid panel.
• Pregnancy status and contraception plans (GLP-1 agonists are not used in pregnancy).
• Realistic goals, including the role of nutrition, sleep, resistance training, and what response would justify continuing therapy at 6 and 12 months.

A clinician-supervised intake like the one at Body Good Men's semaglutide telehealth program collects this information through a structured visit. Eligibility is the prescriber's call — not a checkbox.

Why El Paso patients often choose telehealth

El Paso County is geographically large, and access to in-person obesity-medicine specialists is uneven across the Borderplex. According to the CDC's National Diabetes Statistics Report, Hispanic and Latino adults experience a roughly 1.7-fold higher prevalence of diagnosed diabetes than non-Hispanic white adults (CDC, 2022) — a disparity reflected in El Paso County's adult metabolic burden, where roughly 83% of residents identify as Hispanic or Latino. Texas adults overall report higher obesity prevalence than the national average in CDC Behavioral Risk Factor Surveillance System data.

For men in El Paso, Horizon City, Socorro, and the broader Borderplex, a video visit is a reasonable fit for a candidate evaluation that depends primarily on history, weight, and bloodwork rather than a hands-on exam. The clinician-supervised semaglutide program at Body Good Men was built around that kind of intake — including the option to communicate with the clinical team in Spanish.

Side effects and what to discuss with your provider

The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. They tend to be most prominent during dose escalation and to attenuate over time. The FDA prescribing information for semaglutide also addresses less common but serious considerations — pancreatitis, gallbladder disease, acute kidney injury (often related to dehydration from GI side effects), and worsening of pre-existing diabetic retinopathy — alongside a boxed warning regarding thyroid C-cell tumors observed in rodents.

Useful questions to bring to the conversation with your clinician:

• Given my labs and history, am I a candidate for GLP-1 therapy?
• What is the plan if I develop persistent nausea or other gastrointestinal symptoms?
• How will progress be measured, and what would prompt us to reassess?
• What is the difference between an FDA-approved branded GLP-1 and a compounded preparation, and which is appropriate for my situation?
• Are there other medications, supplements, or conditions in my history that need to be reviewed first?

Compounded vs FDA-approved: a regulatory note

Compounded preparations and FDA-approved branded medications are regulated differently. FDA-approved drugs go through controlled clinical trials and post-market surveillance under a manufacturer's label. State-compounded preparations are made for an individual patient under a clinician's prescription and are governed by state pharmacy boards and federal compounding statutes. They are not held out as identical, equivalent, or interchangeable. The Body Good Men compounded semaglutide pathway is structured around a clinical evaluation, not a transactional purchase.

Frequently asked questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy are FDA-approved branded products from a single manufacturer with controlled formulations and labeling. Compounded semaglutide is a non-FDA-approved preparation made for an individual patient by a state-licensed compounding pharmacy under a clinician's prescription. They are distinct categories and should not be considered interchangeable. A clinician evaluates which option is appropriate based on a patient's full clinical picture.

Who is a candidate for semaglutide therapy?

Eligibility is determined by a licensed clinician. In general, GLP-1 therapy is considered for adults with type 2 diabetes (per ADA guidance) or for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, prediabetes, or obstructive sleep apnea. Pregnancy, certain thyroid conditions, and prior pancreatitis are typical disqualifiers.

How long do people stay on semaglutide?

There is no fixed duration. Obesity is a chronic condition, and the STEP and SELECT trials studied semaglutide for 68 weeks and roughly four years, respectively. Some patients remain on therapy long-term under clinician supervision; others taper or discontinue based on goals, response, side effects, or evolving health needs. Duration is reviewed in follow-up visits with the prescriber rather than decided in advance.

What are the most common side effects?

Gastrointestinal effects — nausea, vomiting, diarrhea, constipation, and abdominal discomfort — are the most frequently reported in clinical trials and FDA prescribing information. They tend to be most prominent during dose escalation and to ease over time. Less common but serious risks include pancreatitis, gallbladder disease, dehydration-related acute kidney injury, and worsening diabetic retinopathy. Discuss your medical history with your provider before starting therapy.

Is semaglutide compounding legal in Texas?

Compounding is legal under federal and state pharmacy law when performed by a state-licensed compounding pharmacy under a clinician's prescription for an individual patient. Texas pharmacy regulation falls under the Texas State Board of Pharmacy. Whether a compounded preparation is appropriate for a specific patient is a clinical decision made by a licensed prescriber — not a regulatory shortcut available directly to consumers.

Talk to a clinician

If you're considering GLP-1 receptor agonist therapy and want to know whether it's appropriate for you, talk to a licensed clinician. The Semaglutide program at Body Good Men connects you with a US-licensed clinician who reviews your eligibility and, if appropriate, prescribes through our partner pharmacy. Begin a telehealth evaluation through the Body Good Men semaglutide intake.

---

Important Disclosure

men.joinbodygood.com is operated as an affiliate of Body Good Studio LLC and is a whitelabel certified partner of Leg Up Rx. men.joinbodygood.com does not provide medical services, prescribe medications, or maintain patient records. All clinical evaluations, prescription decisions, and medication fulfillment are handled by licensed medical and pharmacy partners through Leg Up Rx. This article is for general informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any treatment. Eligibility for any medication is determined solely by a licensed clinician.

---